סימבקסון 40

Страна: Израел

Език: иврит

Източник: Ministry of Health

Купи го сега

Листовка Листовка (PIL)
06-07-2021

Активна съставка:

SIMVASTATIN

Предлага се от:

DEXCEL PHARMA TECHNOLOGIES LTD

АТС код:

C10AA01

Лекарствена форма:

קפליות

Композиция:

SIMVASTATIN 40 MG

Начин на приложение:

פומי

Вид предписание :

מרשם נדרש

Произведено от:

DEXCEL LTD, ISRAEL

Терапевтична група:

SIMVASTATIN

Терапевтична област:

SIMVASTATIN

Терапевтични показания:

Coronary Heart Disease : In patients with coronary heart disease and hypercholesterolemia Simvaxon is indicated to: - Reduce the risk of total mortality by reducing coronary death - Reduce the risk of non-fatal myocardial infarction - Reduce the risk for undergoing myocardial revascularization procedures - Reduce the risk of stroke and transient ischemic attacks (TIA's). Hyperlipidemia: Simvaxon is indicated as an adjunct to diet to reduce elevated TOTAL-C LDL-C Apo B and TG and to increase HDL-C in patients with primary hypercholesterolemia ( heterozygous familial and nonfamilial) and mixed dyslipidemia (Frederickson Types IIa and IIb) Simvaxon therefore lowers the LDL-C/HDL-C and the total-C/HDL-C ratios. Homozygous familial hypercholesterolemia: Simvaxon is also indicated as an adjunct to diet and other non-dietary measures in reducing elevated total cholesterol LDL-cholesterol and apolipoprotein B in patients with homozygous familial hypercholesterolemia when response to these measures is inadequate. Hype

Каталог на резюме:

Atorvastatin, Cerivastatin, Fluvastatin, Lovastatin, Pravastatin, Simvastatin

Дата Оторизация:

2020-04-30

Документи на други езици

Листовка Листовка английски 20-01-2021
Доклад обществена оценка Доклад обществена оценка английски 18-08-2016
Листовка Листовка арабски 20-01-2021

Сигнали за търсене, свързани с този продукт

Преглед на историята на документите